Dacarbazine

Generic Name: Dacarbazine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₀N_₆O

CAS Number: 4342-03-4

Unique Ingredient Identifier: 7GR28W0FJI

Background: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication: For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions: Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-12-28

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 353

Registration Number: NCT00416377

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Lenalidomide
Drug: Dacarbazine

First Posted Date: 2006-12-18

Last Posted Date: 2016-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00412581

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-12-13

Last Posted Date: 2013-08-07

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 642

Registration Number: NCT00410631

Locations: 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪
Klinikum Dortmund, Dortmund, Germany
🇩🇪
Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany

and more 74 locations

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Bleomycin
Biological: Rituximab
Drug: Dacarbazine
Drug: Doxorubicin
Drug: Vinblastine

First Posted Date: 2006-08-29

Last Posted Date: 2018-08-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 51

Registration Number: NCT00369681

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

and more 1 locations

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: imexon
Drug: DTIC

First Posted Date: 2006-05-18

Last Posted Date: 2010-09-15

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 68

Registration Number: NCT00327600

Locations: 🇺🇸
University of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
Investigational Site 012, Salt Lake City, Utah, United States
🇺🇸
US Oncology Greenville, Cancer Centers of the Carolinas, Greenville, South Carolina, United States

and more 8 locations

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: Placebo
Drug: Ipilimumab
Drug: Dacarbazine

First Posted Date: 2006-05-10

Last Posted Date: 2014-11-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 681

Registration Number: NCT00324155

Locations: 🇺🇸
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
St Joseph Oncology Inc, Saint Joseph, Missouri, United States

and more 30 locations

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2006-03-29

Last Posted Date: 2009-04-03

Lead Sponsor: University of Turku

Target Recruit Count: 27

Registration Number: NCT00308607

Locations: 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮
Oulu University Hospital, Oulu, Finland
🇫🇮
Tampere University Hospital, Tampere, Finland

HD11 for Intermediate Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

Interventions: Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: Etoposide
Drug: DTIC
Drug: Procarbazine
Radiation: radiation therapy
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2005-12-13

Last Posted Date: 2011-08-04

Lead Sponsor: University of Cologne

Target Recruit Count: 1395

Registration Number: NCT00264953

HD10 for Early Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

Interventions: Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: DTIC
Radiation: 20 Gy IF-RT
Radiation: 30 Gy IF-RT

First Posted Date: 2005-12-13

Last Posted Date: 2011-07-29

Lead Sponsor: University of Cologne

Target Recruit Count: 1370

Registration Number: NCT00265018

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: CP-675,206
Drug: dacarbazine
Drug: temozolomide

First Posted Date: 2005-11-22

Last Posted Date: 2012-07-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 655

Registration Number: NCT00257205

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy